EE200200667A - Bitsüklilised tsükloheksüülamiinid ja nende kasutamine NMDA retseptori antagonistidena - Google Patents

Bitsüklilised tsükloheksüülamiinid ja nende kasutamine NMDA retseptori antagonistidena

Info

Publication number
EE200200667A
EE200200667A EEP200200667A EEP200200667A EE200200667A EE 200200667 A EE200200667 A EE 200200667A EE P200200667 A EEP200200667 A EE P200200667A EE P200200667 A EEP200200667 A EE P200200667A EE 200200667 A EE200200667 A EE 200200667A
Authority
EE
Estonia
Prior art keywords
cyclohexylamines
bicyclic
receptor antagonists
nmda receptor
nmda
Prior art date
Application number
EEP200200667A
Other languages
English (en)
Estonian (et)
Inventor
Shridhar Nikam Sham
Leslie Scott Ian
Alan Sherer Brian
David Wise Lawrence
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of EE200200667A publication Critical patent/EE200200667A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EEP200200667A 2000-05-31 2001-05-08 Bitsüklilised tsükloheksüülamiinid ja nende kasutamine NMDA retseptori antagonistidena EE200200667A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20824100P 2000-05-31 2000-05-31
PCT/US2001/014763 WO2001092239A1 (en) 2000-05-31 2001-05-08 Biciclic cyclohexylamines and their use as nmda receptor antogonists

Publications (1)

Publication Number Publication Date
EE200200667A true EE200200667A (et) 2004-06-15

Family

ID=22773822

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200667A EE200200667A (et) 2000-05-31 2001-05-08 Bitsüklilised tsükloheksüülamiinid ja nende kasutamine NMDA retseptori antagonistidena

Country Status (28)

Country Link
US (1) US6794402B2 (pl)
EP (1) EP1286975B1 (pl)
JP (1) JP2003535083A (pl)
KR (1) KR20030007797A (pl)
CN (1) CN1438996A (pl)
AP (1) AP2002002697A0 (pl)
AT (1) ATE302763T1 (pl)
AU (1) AU2001259618A1 (pl)
BG (1) BG107375A (pl)
BR (1) BR0111301A (pl)
CA (1) CA2409006A1 (pl)
DE (1) DE60112924T2 (pl)
DZ (1) DZ3361A1 (pl)
EA (1) EA200201158A1 (pl)
EE (1) EE200200667A (pl)
ES (1) ES2245985T3 (pl)
HR (1) HRP20021018A2 (pl)
HU (1) HUP0302323A2 (pl)
IL (1) IL153170A0 (pl)
IS (1) IS6625A (pl)
MA (1) MA26907A1 (pl)
MX (1) MXPA02011926A (pl)
NO (1) NO20025762L (pl)
OA (1) OA12275A (pl)
PL (1) PL359260A1 (pl)
SK (1) SK16632002A3 (pl)
WO (1) WO2001092239A1 (pl)
ZA (1) ZA200209325B (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02002749A (es) * 2001-03-27 2002-10-28 Warner Lambert Co Derivados de ciclohexilamina como antagonistas del subtipo selectivo del n-metil-d-aspartato.
GB0116594D0 (en) 2001-07-06 2001-08-29 Cancer Res Ventures Ltd Therapeutic compounds
DE10210779A1 (de) 2002-03-12 2003-10-09 Merck Patent Gmbh Cyclische Amide
NZ537301A (en) 2002-06-07 2006-06-30 Cortical Pty Ltd Therapeutic molecules and methods-1
BR0215986A (pt) 2002-12-20 2005-11-01 Cancer Rec Tech Ltd Composto, composição, uso de composto, e, método para o tratamento de uma condição proliferativa, para o tratamento de câncer e de uma condição mediada pela tioredoxina/tioredoxina reductase, para inibir a tioredoxina/tioredoxina reductase em uma célula, in vitro ou in vivo e, para regular e inibir a proliferação celular
EP1827468B1 (en) * 2004-12-23 2012-08-22 Curaxis Pharmaceutical Corporation Acetylcholinesterase Inhibitors and leuprolide acetate for the treatment of Alzheimer's disease
JP5270943B2 (ja) * 2008-03-28 2013-08-21 大阪瓦斯株式会社 フルオレン誘導体およびこのフルオレン誘導体を用いたアミノ基含有フルオレン誘導体の製造方法
US9345848B2 (en) 2009-10-20 2016-05-24 Sima Patent Ve Lisanslama Hizmetleri Ltd. Sti. Dry powder inhaler
AR080056A1 (es) * 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
US9216954B2 (en) 2012-01-27 2015-12-22 National University Corporation University Of Toyama Serine racemase inhibitor
CN105001118A (zh) * 2015-07-20 2015-10-28 湖南华腾制药有限公司 一种含碘叠氮化合物的制备方法
CN105152966A (zh) * 2015-07-20 2015-12-16 湖南华腾制药有限公司 一种叠氮化合物的制备方法
CN105061254A (zh) * 2015-07-20 2015-11-18 湖南华腾制药有限公司 一种含溴叠氮化合物的合成方法
CN105153020A (zh) * 2015-07-20 2015-12-16 湖南华腾制药有限公司 一种芳香叠氮化合物的制备方法
WO2018033525A1 (en) * 2016-08-16 2018-02-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Agonists or partial agonists of the histamine site of the nmda receptor for use in the treatment of central nervous system diseases
CN107043335A (zh) * 2017-05-31 2017-08-15 湖南华腾制药有限公司 一种2‑氟苯基叠氮化合物的制备方法
CN118206529A (zh) 2017-09-04 2024-06-18 C4医药公司 二氢苯并咪唑酮
WO2020181232A1 (en) 2019-03-06 2020-09-10 C4 Therapeutics, Inc. Heterocyclic compounds for medical treatment
WO2025232878A1 (zh) * 2024-05-09 2025-11-13 苏州旺山旺水生物医药股份有限公司 一类含取代的苯基的胺类化合物、其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4438055A1 (de) * 1994-10-25 1996-05-02 Thomae Gmbh Dr K Ring- und N-substituierte N-Benzyl-cycloalkylamine, ihre Salze mit physiologisch verträglichen organischen oder anorganischen Säuren, Verfahren zur Herstellung dieser Verbindungen und diese enthaltende Arzneimittel
DE19812331A1 (de) * 1998-03-20 1999-09-23 Merck Patent Gmbh Piperidinderivate
EP0982026B1 (en) * 1998-08-18 2006-05-17 F. Hoffmann-La Roche Ag Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers

Also Published As

Publication number Publication date
CA2409006A1 (en) 2001-12-06
AP2002002697A0 (en) 2002-12-31
HRP20021018A2 (en) 2004-02-29
ATE302763T1 (de) 2005-09-15
IS6625A (is) 2002-11-18
ZA200209325B (en) 2004-02-16
PL359260A1 (pl) 2004-08-23
KR20030007797A (ko) 2003-01-23
DE60112924T2 (de) 2006-03-16
DE60112924D1 (de) 2005-09-29
US20030236252A1 (en) 2003-12-25
ES2245985T3 (es) 2006-02-01
BR0111301A (pt) 2003-06-10
EP1286975B1 (en) 2005-08-24
NO20025762L (no) 2003-01-09
MXPA02011926A (es) 2003-04-22
NO20025762D0 (no) 2002-11-29
EP1286975A1 (en) 2003-03-05
CN1438996A (zh) 2003-08-27
BG107375A (bg) 2003-09-30
AU2001259618A1 (en) 2001-12-11
EA200201158A1 (ru) 2003-04-24
JP2003535083A (ja) 2003-11-25
DZ3361A1 (fr) 2001-12-06
WO2001092239A1 (en) 2001-12-06
MA26907A1 (fr) 2004-12-20
US6794402B2 (en) 2004-09-21
HUP0302323A2 (hu) 2003-10-28
OA12275A (en) 2003-12-11
SK16632002A3 (sk) 2003-08-05
IL153170A0 (en) 2003-06-24

Similar Documents

Publication Publication Date Title
EE200200667A (et) Bitsüklilised tsükloheksüülamiinid ja nende kasutamine NMDA retseptori antagonistidena
EE200000778A (et) 4-bensüülpiperidiinalküülsulfoksiidi heterotsüklid ja nende kasutamine NMDA retseptori alaliikide suhtes selektiivsete antagonistidena
IL152700A0 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinc receptor antagonists
IL162825A0 (en) Fluoro substituted cycloalkanoindoles and their use asprotaglandin d2 receptor antagonists
IS7801A (is) Púrín efnasambönd og notkun þeirra sem kannabinóíð viðtaka bindla
EE200400025A (et) 5-HT retseptori ligandid ja nende kasutamine
DK1345920T3 (da) Hidtil ukendte sulfamider og anvendelse deraf som endothelinreceptorantagonister
ATE368659T1 (de) Thrombinrezeptorantagonisten
PT1009732E (pt) 1-amino-alquilciclo-hexanos antagonistas do receptor nmda
EE200300191A (et) Alfa-arüül-etanoolamiinid ja nende kasutamine beeta-3 adrenergiliste retseptorite agonistidena
EE200200400A (et) Kortikotropiini vabastava faktori antagonistid
NO20032612D0 (no) CXCR3-antagonister
EP1390034A4 (en) N-SUBSTITUTED NONARYL HETEROCYCLO AMIDYL-NMDA / NR2B ANTAGONISTS
IL152701A0 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
AU2002352476A8 (en) Urea derivatives and their use as vanilloid receptor antagonists
HUP0300599A3 (en) Il-8 receptor antagonists, pharmaceutical compositions containing them and their use
AU9259801A (en) Alpha v integrin receptor antagonists
ATE374183T1 (de) Nk1-antagonisten
EP1171152A4 (en) VMIP-II PEPTIDE ANTAGONISTS OF CXCR4
AUPQ570100A0 (en) Beta-alanine derivatives and their use as receptor antagonists
PL370221A1 (pl) 2-Oksazoloaminy oraz zastosowanie ich jako antagonistów receptora 5-HT2B
HUP0300470A3 (en) Il-8 receptor antagonists, pharmaceutical compositions containing them and their use
DE60222015D1 (de) Ccr-3-rezeptorantagonisten vii
ATE320254T1 (de) Crf receptor antagonisten
HUP0300305A3 (en) Il-8 receptor antagonists, pharmaceutical compositions containing them and their use